Transdermal Diagnostics Ltd, founded in 2021, is a promising spin-out from the University of Bath, operating in the Biotechnology and Health Care sectors. The company is dedicated to developing the world's first wearable for non-invasive continuous biomarker co-monitoring, aiming to innovate the MedTech landscape.
This venture is building a revolutionary, 100% needle-free, pain-free continuous glucose monitor (CGM) targeting chronic conditions such as diabetes and obesity. The device seeks to empower users by offering personalized insights and aiding in informed health decisions, ultimately enhancing patient care and lifestyle quality.
Recently, Transdermal Diagnostics secured a Seed investment on 01 February 2024, backed by notable investors including Qubis, Bristol Private Equity Club, Science Angel Syndicate, Immetric, and Pioneer Group. This injection of capital positions the company well for accelerating its groundbreaking developments.
